Efficacy prediction and molecular mechanism of thyroid hormone levels and multi-target TKI therapy for renal cell carcinoma and hepatocellular carcinoma

Yueqin Sun, Aimin Li, Yue Luo, Zheng-Xiang Song, Xue-Wei Zhuang, Guanqi Dai
{"title":"Efficacy prediction and molecular mechanism of thyroid hormone levels and multi-target TKI therapy for renal cell carcinoma and hepatocellular carcinoma","authors":"Yueqin Sun, Aimin Li, Yue Luo, Zheng-Xiang Song, Xue-Wei Zhuang, Guanqi Dai","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.05.011","DOIUrl":null,"url":null,"abstract":"Hypothyroidism is a common adverse reaction in clinical multi-target tyrosine kinase inhibitor (TKI) and may be used as a predictor of efficacy of TKI drugs. Studies show that hypothyroidism is significantly associated with good prognosis in patients with renal cell carcinoma treated with multi-target TKI, which may be related to inhibition of vascular endothelial growth factor receptor pathway, potential off-target effects and inhibition of cell proliferation. Whereas in the patients with hepatocellular carcinoma who received multi-target TKI therapy, hypothyroidism is an indicator of poor prognosis, which is related to the T3/TR pathway regulating liver cancer growth and invasion. The predictive function and mechanism of thyroid hormone levels in different tumor patients receiving multi-target TKI drugs are different, and further research is still needed. \n \n \nKey words: \nThyroid hormones; Neoplasms; Prognosis; Tyrosine kinase inhibitors","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"27 1","pages":"303-306"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.05.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hypothyroidism is a common adverse reaction in clinical multi-target tyrosine kinase inhibitor (TKI) and may be used as a predictor of efficacy of TKI drugs. Studies show that hypothyroidism is significantly associated with good prognosis in patients with renal cell carcinoma treated with multi-target TKI, which may be related to inhibition of vascular endothelial growth factor receptor pathway, potential off-target effects and inhibition of cell proliferation. Whereas in the patients with hepatocellular carcinoma who received multi-target TKI therapy, hypothyroidism is an indicator of poor prognosis, which is related to the T3/TR pathway regulating liver cancer growth and invasion. The predictive function and mechanism of thyroid hormone levels in different tumor patients receiving multi-target TKI drugs are different, and further research is still needed. Key words: Thyroid hormones; Neoplasms; Prognosis; Tyrosine kinase inhibitors
甲状腺激素水平及多靶点TKI治疗肾细胞癌和肝细胞癌的疗效预测及分子机制
甲状腺功能减退是临床多靶点酪氨酸激酶抑制剂(TKI)常见的不良反应,可作为TKI药物疗效的预测指标。研究表明,多靶点TKI治疗肾癌患者甲状腺功能减退与预后良好显著相关,这可能与抑制血管内皮生长因子受体通路、潜在脱靶效应、抑制细胞增殖有关。而在接受多靶点TKI治疗的肝癌患者中,甲状腺功能减退是预后不良的一个指标,这与调节肝癌生长和侵袭的T3/TR通路有关。甲状腺激素水平对不同肿瘤患者接受多靶点TKI药物的预测功能及机制存在差异,有待进一步研究。关键词:甲状腺激素;肿瘤;预后;酪氨酸激酶抑制剂
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
12123
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信